,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,LCE3E,LEP17,ENSG00000185966,Late cornified envelope 3E,1,152565654-152566772,Predicted intracellular proteins,Evidence at protein level,,,,,,,Group enriched,Group enriched,35,esophagus: 9.6;skin: 9.0;tonsil: 18.1,breast: 0.3,Not detected,,
1,RPTN,FLJ39117,ENSG00000215853,Repetin,1,152153595-152159228,Predicted intracellular proteins,Evidence at protein level,"HPA030483, HPA030485",Enhanced,,,,,Tissue enhanced,Group enriched,34,skin: 35.1;tonsil: 47.4,esophagus: 1.2,Not detected,,
2,SLURP1,"ANUP, ARS, ArsB, LY6LS, MDM",ENSG00000126233,Secreted LY6/PLAUR domain containing 1,8,142740944-142742411,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA050967,Approved,,,,,Tissue enhanced,Group enriched,33,esophagus: 740.6;skin: 297.1,tonsil: 15.7,Cell line enhanced,,HaCaT: 1.1;MCF7: 1.1;T-47d: 2.4
3,CNFN,PLAC8L2,ENSG00000105427,Cornifelin,19,42387019-42390287,Predicted intracellular proteins,Evidence at protein level,"HPA049073, HPA053997",Enhanced,,Approved,Microtubules<br>Cytokinetic bridge,Thyroid cancer:4.02e-5 (favourable),Expressed in all,Group enriched,32,esophagus: 1158.0;skin: 272.5;tonsil: 260.7,breast: 17.6,Cell line enhanced,,A549: 17.1;HEK93: 24.4
4,PLA2G4D,cPLA2delta,ENSG00000159337,Phospholipase A2 group IVD,15,42067009-42094554,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,29,prostate: 34.2;skin: 16.5,esophagus: 0.8,Cell line enriched,30.0,RPMI-8226: 12.2
5,SPINK5,"DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI",ENSG00000133710,"Serine peptidase inhibitor, Kazal type 5",5,148025683-148137289,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA009067, HPA011351, CAB015347",Enhanced,,Enhanced,Vesicles,,Tissue enhanced,Group enriched,26,esophagus: 1130.0;skin: 383.9;tonsil: 270.0,breast: 22.9,Cell line enhanced,,HaCaT: 13.2;HeLa: 14.7;Karpas-707: 13.8
6,TRPM1,"CSNB1C, LTRPC1, MLSN1",ENSG00000134160,Transient receptor potential cation channel subfamily M member 1,15,31001061-31161273,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA014779, HPA014785",Supported,,Uncertain,Nucleoplasm<br>Cytosol,,Tissue enriched,Group enriched,26,skin: 4.8;testis: 2.1,kidney: 0.1,Cell line enriched,91.0,SK-MEL-30: 9.1
7,DGAT2L6,"DC3, FLJ25989",ENSG00000184210,Diacylglycerol O-acyltransferase 2 like 6,X,70177483-70205545,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,22,breast: 2.8;skin: 1.6,all non-specific tissues: 0.0,Not detected,,
8,NCCRP1,"FBXO50, LOC342897, NCCRP-1",ENSG00000188505,Non-specific cytotoxic cell receptor protein 1 homolog (zebrafish),19,39196961-39201884,Predicted intracellular proteins,Evidence at protein level,HPA052812,Uncertain,,Approved,Mitochondria,Endometrial cancer:1.01e-4 (unfavourable),Mixed,Group enriched,22,esophagus: 263.4;skin: 175.5;tonsil: 113.3,breast: 8.2,Cell line enriched,7.0,SK-BR-3: 23.1
9,SLC24A5,"JSX, OCA6",ENSG00000188467,Solute carrier family 24 member 5,15,48120972-48142672,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,21,skin: 9.6;testis: 2.9,breast: 0.3,Cell line enriched,760.0,SK-MEL-30: 193.4
10,KRTAP21-2,KAP21.2,ENSG00000187026,Keratin associated protein 21-2,21,30746794-30747233,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,20,skin: 1.1;testis: 2.9,all non-specific tissues: 0.0,Cell line enriched,12.0,HEK93: 1.7
11,SPRR2B,,ENSG00000196805,Small proline rich protein 2B,1,153070224-153070840,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,18,esophagus: 30.3;skin: 17.1;testis: 8.2;tonsil: 14.1,ovary: 0.9,Not detected,,
12,SPRR2E,,ENSG00000203785,Small proline rich protein 2E,1,153093135-153106184,Predicted intracellular proteins,Evidence at transcript level,,,,,,Urothelial cancer:9.47e-4 (unfavourable),Tissue enhanced,Group enriched,18,esophagus: 2005.4;skin: 804.8;tonsil: 459.7,breast: 61.4,Cell line enriched,9.0,hTCEpi: 12.1
13,FAM83C,"C20orf128, dJ614O4.7",ENSG00000125998,Family with sequence similarity 83 member C,20,35285731-35292401,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034227, HPA049978",Uncertain,,,,,Tissue enhanced,Group enriched,17,esophagus: 19.8;skin: 43.0,tonsil: 1.8,Not detected,,
14,ELMOD1,DKFZp547C176,ENSG00000110675,ELMO domain containing 1,11,107591091-107666779,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038434, HPA038435",,,Supported,Nucleoplasm<br>Cytosol,,Tissue enriched,Group enriched,15,cerebral cortex: 71.3;skin: 36.7,"adrenal gland,fallopian tube: 3.5",Cell line enhanced,,HUVEC TERT2: 12.8;RH-30: 33.5
15,FAM25C,bA164N7.4,ENSG00000276430,Family with sequence similarity 25 member C,10,47995355-47999791,Predicted intracellular proteins,Evidence at transcript level,HPA044808,Uncertain,,,,,Tissue enhanced,Group enriched,14,breast: 5.3;esophagus: 4.0;skin: 9.0;small intestine: 4.3;tonsil: 2.1,"skeletal muscle,testis: 0.3",Cell line enriched,5.0,SK-BR-3: 12.1
16,KRT32,"Ha-2, KRTHA2",ENSG00000108759,Keratin 32,17,41459811-41467429,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,14,esophagus: 7.4;skin: 2.4,breast: 0.3,Not detected,,
17,S100A7A,"S100A15, S100A7f, S100A7L1",ENSG00000184330,S100 calcium binding protein A7A,1,153416524-153423225,Predicted intracellular proteins,Evidence at protein level,HPA006997,Supported,,,,,Tissue enhanced,Group enriched,14,skin: 1.9;tonsil: 5.4,"esophagus,testis: 0.2",Not detected,,
18,EN1,,ENSG00000163064,Engrailed homeobox 1,2,118842171-118847678,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB014884, HPA073141",Approved,,Supported,Nucleus<br>Nucleoli,,Tissue enhanced,Group enriched,13,adipose tissue: 1.3;breast: 1.0;lymph node: 1.9;skeletal muscle: 4.7;skin: 2.2,testis: 0.1,Cell line enhanced,,ASC diff: 10.8;fHDF/TERT166: 10.2;HSkMC: 9.7;PC-3: 7.1;U-138 MG: 9.6;U-2197: 10.2
19,DSC3,"CDHF3, DSC, DSC1, DSC2, DSC4",ENSG00000134762,Desmocollin 3,18,30990008-31042815,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB037328, HPA049265, HPA073937",Enhanced,,Enhanced,Plasma membrane<br>Cell Junctions,Urothelial cancer:1.04e-5 (unfavourable),Tissue enhanced,Group enriched,12,esophagus: 119.1;skin: 454.8,tonsil: 24.8,Cell line enhanced,,HaCaT: 242.4;hTCEpi: 115.0;hTERT-HME1: 89.5
20,RP11-119J18.1,,ENSG00000250378,,5,135812667-135826584,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,12,skin: 2.1;testis: 4.6,"breast,duodenum,esophagus,kidney: 0.2",Cell line enhanced,,HEL: 1.4;SK-MEL-30: 1.3
21,SBSN,"HLAR698, UNQ698",ENSG00000189001,Suprabasin,19,35523367-35528351,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA062568, HPA067734",Enhanced,,Approved,Vesicles,,Group enriched,Group enriched,12,esophagus: 1055.9;skin: 2690.8,tonsil: 151.8,Cell line enhanced,,ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4
22,CRCT1,"C1orf42, NICE-1",ENSG00000169509,Cysteine rich C-terminal 1,1,152514502-152516010,Predicted intracellular proteins,Evidence at protein level,,,,,,Pancreatic cancer:7.03e-4 (unfavourable),Tissue enhanced,Group enriched,11,esophagus: 84.0;skin: 82.8;tonsil: 17.6,breast: 5.6,Cell line enriched,14.0,CAPAN-2: 4.5
23,GRHL3,"SOM, TFCP2L4",ENSG00000158055,Grainyhead like transcription factor 3,1,24319322-24364482,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA059960,Enhanced,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,11,esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1,testis: 4.3,Cell line enhanced,,BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5
24,LRIT2,"AC022389.4, LRRC22",ENSG00000204033,"Leucine rich repeat, Ig-like and transmembrane domains 2",10,84220495-84225589,Predicted membrane proteins,Evidence at protein level,HPA037788,Supported,,,,,Not detected,Group enriched,11,cerebral cortex: 1.0;skin: 3.1,"colon,esophagus,small intestine,spleen,testis: 0.1",Not detected,,
25,LY6D,E48,ENSG00000167656,Lymphocyte antigen 6 family member D,8,142784880-142786592,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA024755, HPA064317",Enhanced,,,,"Pancreatic cancer:1.94e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable)",Group enriched,Group enriched,11,esophagus: 631.6;skin: 717.0,tonsil: 61.0,Cell line enriched,26.0,A-431: 128.0
26,LYNX1,,ENSG00000283992,Ly6/neurotoxin 1,8,142764338-142769844,"Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,,Group enriched,11,esophagus: 315.6;skin: 108.1,tonsil: 19.9,Group enriched,16.0,EFO-21: 5.6;HaCaT: 24.1
27,PKP1,B6P,ENSG00000081277,Plakophilin 1,1,201283452-201332993,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027221, HPA027589, CAB033130",Enhanced,,Enhanced,Nucleoplasm,,Tissue enhanced,Group enriched,11,esophagus: 281.6;skin: 821.6,prostate: 51.7,Cell line enhanced,,HaCaT: 205.1;HBEC3-KT: 102.1;hTCEpi: 358.4;hTERT-HME1: 100.7;PC-3: 176.6
28,PLA2G2F,,ENSG00000158786,Phospholipase A2 group IIF,1,20139326-20150386,"Enzymes, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,,,,,,Urothelial cancer:3.86e-4 (favourable),Tissue enriched,Group enriched,11,skin: 11.3;tonsil: 7.2;urinary bladder: 3.9,gallbladder: 0.6,Cell line enriched,57.0,RT4: 110.7
29,PLEKHN1,DKFZP434H2010,ENSG00000187583,Pleckstrin homology domain containing N1,1,966497-975865,Predicted intracellular proteins,Evidence at protein level,HPA031742,Uncertain,,Approved,Nuclear speckles,Renal cancer:4.97e-5 (unfavourable),Mixed,Group enriched,11,esophagus: 16.9;skin: 44.0,urinary bladder: 2.7,Cell line enhanced,,HaCaT: 22.0
30,POU2F3,"Epoc-1, OCT11, PLA-1, Skn-1a",ENSG00000137709,POU class 2 homeobox 3,11,120236640-120319944,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA019652,Enhanced,,,,Thyroid cancer:8.14e-4 (favourable),Mixed,Group enriched,11,parathyroid gland: 15.5;skin: 72.3,seminal vesicle: 3.8,Cell line enhanced,,CAPAN-2: 3.7;SK-BR-3: 2.2;T-47d: 5.2
31,SLC39A2,ZIP2,ENSG00000165794,Solute carrier family 39 member 2,14,20999255-21001871,Predicted membrane proteins,Evidence at protein level,HPA030489,Uncertain,,,,,Mixed,Group enriched,11,esophagus: 19.0;prostate: 19.2;seminal vesicle: 46.9;skin: 34.1,breast: 2.6,Cell line enriched,67.0,HaCaT: 20.5
32,CHP2,,ENSG00000166869,Calcineurin like EF-hand protein 2,16,23754627-23758951,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,CAB072806,Approved,,,,,Tissue enhanced,Group enriched,10,colon: 119.1;duodenum: 252.0;rectum: 127.6;skin: 143.8;small intestine: 227.3,"cervix, uterine: 17.1",Cell line enhanced,,hTERT-HME1: 4.5;NB-4: 4.6
33,CSAG3,CSAG3A,ENSG00000268916,CSAG family member 3,X,152753921-152760222,Predicted intracellular proteins,Evidence at transcript level,HPA078264,,,Approved,Vesicles,,Mixed,Group enriched,10,lymph node: 1.7;skin: 1.2;spleen: 1.9;testis: 4.2,"adipose tissue,lung,placenta: 0.2",Cell line enhanced,,HDLM-2: 23.7;HMC-1: 22.9;SH-SY5Y: 35.8;SK-BR-3: 23.6;U-2 OS: 25.4;U-266/70: 61.5;U-266/84: 30.6
34,IL36G,"IL-1F9, IL-1H1, IL-1RP2, IL1E, IL1F9, IL1H1",ENSG00000136688,"Interleukin 36, gamma",2,112973203-112985665,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,10,skin: 15.8;tonsil: 39.2,esophagus: 2.7,Not detected,,
35,KCTD4,bA321C24.3,ENSG00000180332,Potassium channel tetramerization domain containing 4,13,45192853-45194717,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040734,Uncertain,,Approved,Microtubule organizing center,,Group enriched,Group enriched,10,cerebral cortex: 17.7;skin: 3.7,gallbladder: 1.1,Cell line enhanced,,RPTEC TERT1: 8.8;U-138 MG: 13.7;U-87 MG: 27.1
36,SLC52A1,"FLJ10060, GPCR42, GPR172B, hRFT1, PAR2, RFVT1",ENSG00000132517,Solute carrier family 52 member 1,17,5032600-5052009,"Disease related genes, Predicted membrane proteins",Evidence at protein level,CAB011449,Uncertain,,,,Cervical cancer:9.54e-4 (favourable),Mixed,Group enriched,10,duodenum: 36.1;placenta: 26.1;skin: 13.2;small intestine: 26.3,parathyroid gland: 2.6,Cell line enhanced,,A549: 2.1;BEWO: 1.9;HMC-1: 4.1;SK-BR-3: 2.0
37,SLC9C1,"NHE, SLC9A10",ENSG00000172139,Solute carrier family 9 member C1,3,112140887-112294258,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Not detected,Group enriched,10,skin: 2.9;testis: 14.1,thyroid gland: 0.8,Not detected,,
38,CERS3,"LASS3, MGC27091",ENSG00000154227,Ceramide synthase 3,15,100400395-100544995,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006092, HPA024356",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,9,esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3,breast: 4.3,Cell line enriched,6.0,hTCEpi: 47.1
39,EVPL,EVPK,ENSG00000167880,Envoplakin,17,76004502-76027452,Predicted intracellular proteins,Evidence at protein level,"CAB002220, HPA053969",Enhanced,,Supported,Intermediate filaments<br>Cytosol,,Mixed,Group enriched,9,esophagus: 77.5;skin: 111.0,duodenum: 10.7,Cell line enhanced,,HaCaT: 51.8;RT4: 68.1;T-47d: 50.1
40,HOXC10,HOX3I,ENSG00000180818,Homeobox C10,12,53985065-53990279,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA053919,Uncertain,,Supported,Nucleoplasm<br>Nuclear bodies,,Mixed,Group enriched,9,kidney: 18.9;skeletal muscle: 40.3;skin: 8.4,breast: 2.5,Cell line enhanced,,AN3-CA: 275.9;T-47d: 95.2
41,IL20RB,"DIRS1, FNDC6, IL-20R2, MGC34923",ENSG00000174564,Interleukin 20 receptor subunit beta,3,136946230-137011085,Predicted membrane proteins,Evidence at protein level,HPA063914,,,Approved,Vesicles<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.44e-4 (unfavourable)",Group enriched,Group enriched,9,esophagus: 56.6;skin: 165.5,breast: 12.4,Cell line enhanced,,HaCaT: 70.0;HBEC3-KT: 93.7;HHSteC: 70.6;hTCEpi: 372.4;hTERT-HME1: 73.1
42,KRT5,"EBS2, KRT5A",ENSG00000186081,Keratin 5,12,52514575-52520687,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000027, CAB000129, HPA059479",Enhanced,,Supported,Intermediate filaments,Breast cancer:1.27e-4 (favourable),Tissue enhanced,Group enriched,9,esophagus: 3256.1;skin: 5996.8,tonsil: 516.9,Group enriched,6.0,HaCaT: 2557.9;HBEC3-KT: 3723.5;hTCEpi: 8392.0
43,KRT79,"K6L, KRT6L",ENSG00000185640,Keratin 79,12,52821410-52834295,Predicted intracellular proteins,Evidence at protein level,HPA059347,Enhanced,,,,,Group enriched,Group enriched,9,breast: 4.0;skin: 17.1,esophagus: 1.1,Cell line enriched,18.0,HMC-1: 375.1
44,PGLYRP3,"PGLYRPIalpha, PGRP-Ialpha, PGRPIA",ENSG00000159527,Peptidoglycan recognition protein 3,1,153297862-153310718,Predicted secreted proteins,Evidence at protein level,HPA030369,Uncertain,,,,,Tissue enhanced,Group enriched,9,esophagus: 42.8;skin: 87.1,tonsil: 6.8,Group enriched,15.0,HaCaT: 3.4;HDLM-2: 1.4;hTCEpi: 1.0
45,ADGRF4,"FLJ38076, GPR115, PGR18",ENSG00000153294,Adhesion G protein-coupled receptor F4,6,47685864-47722021,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA007131, HPA007158",Enhanced,,Uncertain,Mitochondria,Pancreatic cancer:5.52e-4 (unfavourable),Mixed,Group enriched,8,esophagus: 12.1;skin: 45.8,tonsil: 3.7,Cell line enhanced,,HaCaT: 11.5;HBEC3-KT: 14.9;hTCEpi: 22.8;U-87 MG: 25.8
46,ALOX12,12S-LOX,ENSG00000108839,"Arachidonate 12-lipoxygenase, 12S type",17,6996065-7010736,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA010691, CAB019287",Approved,,Supported,Nuclear speckles<br>Cytosol,,Mixed,Group enriched,8,esophagus: 50.3;skin: 25.9,gallbladder: 5.0,Group enriched,5.0,A-431: 22.4;HEL: 36.7
47,C5orf46,"MGC23985, SSSP1",ENSG00000178776,Chromosome 5 open reading frame 46,5,147880726-147906538,Predicted secreted proteins,Evidence at transcript level,HPA058999,,,Approved,Nuclear speckles<br>Mitochondria,"Renal cancer:1.75e-9 (unfavourable), Cervical cancer:3.98e-4 (unfavourable)",Tissue enhanced,Group enriched,8,breast: 17.6;salivary gland: 77.2;skin: 62.4;testis: 19.9,heart muscle: 5.8,Cell line enhanced,,PC-3: 83.2;SiHa: 21.5;U-2 OS: 59.9;U-251 MG: 19.3
48,CALML5,CLSP,ENSG00000178372,Calmodulin like 5,10,5498697-5499555,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA040725,Enhanced,,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:2.59e-5 (favourable),Group enriched,Group enriched,8,salivary gland: 260.7;skin: 650.6,breast: 55.6,Cell line enriched,24.0,A-431: 355.7
49,DSP,"DPI, DPII, KPPS2, PPKS2",ENSG00000096696,Desmoplakin,6,7541575-7586717,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037324, HPA045840, HPA054950",Enhanced,,Enhanced,Cell Junctions,"Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable)",Tissue enhanced,Group enriched,8,esophagus: 345.7;skin: 1016.4,placenta: 89.1,Cell line enhanced,,BEWO: 263.2;HaCaT: 265.1;hTCEpi: 482.9
50,HAL,HIS,ENSG00000084110,Histidine ammonia-lyase,12,95972662-95996365,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038547, HPA038548",Enhanced,,Uncertain,Cytosol,,Tissue enriched,Group enriched,8,liver: 51.2;skin: 72.5,bone marrow: 7.4,Cell line enhanced,,BEWO: 2.1;THP-1: 7.4
51,KCNJ18,"KIR2.6, TTPP2",ENSG00000260458,Potassium voltage-gated channel subfamily J member 18,17,21692523-21704612,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA027021,Uncertain,,Uncertain,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Tissue enhanced,Group enriched,8,skin: 3.8;tonsil: 1.3,testis: 0.3,Not detected,,
52,PAX3,"HUP2, WS1",ENSG00000135903,Paired box 3,2,222199888-222298996,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA063659, HPA069000",Approved,,Supported,Nucleoplasm,,Tissue enriched,Group enriched,8,breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4,prostate: 0.2,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 9.6;BJ hTERT+ SV40 Large T+ RasG12V: 11.6;RH-30: 16.2;SK-MEL-30: 24.6
53,SFN,YWHAS,ENSG00000175793,Stratifin,1,26863138-26864457,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB006268, HPA011105, CAB040552",Enhanced,,Supported,Cytosol,"Renal cancer:7.45e-6 (unfavourable), Liver cancer:5.68e-5 (unfavourable), Endometrial cancer:1.92e-4 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)",Expressed in all,Group enriched,8,esophagus: 1090.0;skin: 1156.7,tonsil: 132.7,Cell line enhanced,,A-431: 663.2;HaCaT: 1030.0;HBEC3-KT: 1288.5;hTCEpi: 852.9
54,TMEM40,FLJ11036,ENSG00000088726,Transmembrane protein 40,3,12733525-12769457,Predicted membrane proteins,Evidence at protein level,HPA044165,Enhanced,,Approved,Cytosol,,Tissue enhanced,Group enriched,8,esophagus: 88.8;placenta: 23.3;skin: 55.5;tonsil: 23.7,urinary bladder: 6.1,Cell line enhanced,,HBEC3-KT: 182.0;hTCEpi: 40.5;hTERT-HME1: 54.0
55,ALDH3A1,ALDH3,ENSG00000108602,Aldehyde dehydrogenase 3 family member A1,17,19737984-19748943,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB045957, HPA051150, HPA063783",Enhanced,,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Head and neck cancer:7.55e-5 (favourable),Mixed,Group enriched,7,esophagus: 406.1;skin: 84.3;stomach: 207.2,tonsil: 31.0,Cell line enriched,21.0,A549: 4306.9
56,ALOX12B,12R-LOX,ENSG00000179477,"Arachidonate 12-lipoxygenase, 12R type",17,8072636-8087703,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA024002,Supported,,Approved,Cytosol,,Group enriched,Group enriched,7,skin: 70.0;tonsil: 17.2,esophagus: 6.2,Cell line enhanced,,HEK93: 1.2;hTCEpi: 1.0
57,ANXA8L1,"ANXA8L2, bA145E20.2, bA301J7.3",ENSG00000264230,Annexin A8-like 1,10,46375627-46537864,Predicted intracellular proteins,Evidence at protein level,"HPA045246, HPA047451",,,Approved,Nucleoplasm,,Mixed,Group enriched,7,esophagus: 199.3;skin: 460.9,urinary bladder: 44.2,Cell line enhanced,,HaCaT: 384.4;HBEC3-KT: 476.5;hTCEpi: 124.5;SiHa: 166.0
58,ARHGAP40,"C20orf95, dJ1100H13.4",ENSG00000124143,Rho GTPase activating protein 40,20,38601934-38651035,Predicted intracellular proteins,Evidence at protein level,"HPA042636, HPA042840",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:2.89e-4 (unfavourable),Mixed,Group enriched,7,breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8,prostate: 4.4,Cell line enhanced,,BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4
59,BNIPL,"BNIP-S, BNIP-Salpha, BNIP-Sbeta, BNIPl-1, BNIPL-2, PP753",ENSG00000163141,BCL2 interacting protein like,1,151036570-151047600,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA019946,,,Approved,Cytosol,"Thyroid cancer:4.32e-4 (favourable), Endometrial cancer:6.50e-4 (unfavourable)",Mixed,Group enriched,7,esophagus: 88.9;skin: 227.0,breast: 21.6,Cell line enriched,14.0,T-47d: 44.3
60,BTBD16,"C10orf87, Em:AC061711.1, FLJ25359",ENSG00000138152,BTB domain containing 16,10,122271306-122338162,Predicted intracellular proteins,Evidence at protein level,"HPA040529, HPA057638",Uncertain,,Uncertain,Nucleoli<br>Cytosol,Renal cancer:1.50e-4 (unfavourable),Tissue enriched,Group enriched,7,skin: 9.9;testis: 14.2;urinary bladder: 19.0,liver: 2.1,Cell line enriched,9.0,RT4: 26.9
61,CARD18,"ICEBERG, pseudo-ICE, UNQ5804",ENSG00000255501,Caspase recruitment domain family member 18,11,105137721-105139726,Predicted intracellular proteins,Evidence at protein level,HPA038582,Approved,,,,,Tissue enhanced,Group enriched,7,breast: 10.6;skin: 29.7,esophagus: 3.0,Cell line enhanced,,BEWO: 3.0;hTCEpi: 1.9;U-2 OS: 2.9
62,CDR1,"CDR, CDR34, CDR62A",ENSG00000184258,Cerebellar degeneration related protein 1,X,140782405-140784871,Predicted intracellular proteins,Evidence at protein level,HPA073147,,,Approved,Nucleoplasm<br>Golgi apparatus<br>Centrosome,,Not detected,Group enriched,7,cerebral cortex: 48.4;skin: 12.1,adipose tissue: 4.0,Cell line enhanced,,BJ: 6.3;U-87 MG: 26.1
63,CES4A,"CES8, FLJ37464",ENSG00000172824,Carboxylesterase 4A,16,66988589-67009758,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035701,Approved,,Approved,Cytosol,Renal cancer:2.35e-6 (unfavourable),Mixed,Group enriched,7,fallopian tube: 28.9;skin: 9.2,epididymis: 2.7,Cell line enhanced,,HDLM-2: 17.6;SiHa: 4.2
64,EPHX3,"ABHD9, FLJ22408",ENSG00000105131,Epoxide hydrolase 3,19,15226919-15233435,Predicted secreted proteins,Evidence at transcript level,HPA012842,Uncertain,,,,Head and neck cancer:2.27e-5 (favourable),Tissue enhanced,Group enriched,7,esophagus: 35.1;skin: 62.8;tonsil: 24.3,parathyroid gland: 5.5,Cell line enhanced,,EFO-21: 2.3;NTERA-2: 2.3;SCLC-21H: 1.2
65,GOLGA7B,"bA451M19.3, bA459F3.4, C10orf132, C10orf133",ENSG00000155265,Golgin A7 family member B,10,97850239-97871580,Predicted intracellular proteins,Evidence at protein level,HPA046878,Uncertain,,,,,Mixed,Group enriched,7,cerebral cortex: 18.3;epididymis: 28.5;skin: 17.4,adrenal gland: 3.1,Cell line enhanced,,A-431: 4.7;HDLM-2: 5.4;SK-MEL-30: 17.6
66,HEATR4,MGC48595,ENSG00000187105,HEAT repeat containing 4,14,73478484-73558947,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,7,skin: 4.4;testis: 21.6,"duodenum,lymph node: 1.9",Cell line enhanced,,SCLC-21H: 2.9
67,IL36RN,"FIL1, FIL1(DELTA), FIL1D, IL-1F5, IL1F5, IL1HY1, IL1L1, IL1RP3, IL36RA, MGC29840",ENSG00000136695,Interleukin 36 receptor antagonist,2,113058638-113065382,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA034542,Uncertain,,,,,Tissue enriched,Group enriched,7,esophagus: 17.2;skin: 40.7;tonsil: 38.1,placenta: 4.7,Group enriched,18.0,BEWO: 25.1;U-87 MG: 19.4
68,IVL,,ENSG00000163207,Involucrin,1,152908545-152911886,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002243, HPA055211",Enhanced,,Supported,Nuclear bodies<br>Centrosome<br>Cytosol,,Group enriched,Group enriched,7,esophagus: 308.3;skin: 131.2,tonsil: 32.9,Group enriched,24.0,HaCaT: 256.2;RT4: 61.2;SK-BR-3: 64.8
69,KRT15,"CK15, K15, K1CO",ENSG00000171346,Keratin 15,17,41513743-41522529,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023910, HPA024554",Enhanced,,Supported,Nucleoplasm<br>Intermediate filaments,Breast cancer:4.50e-4 (favourable),Tissue enhanced,Group enriched,7,breast: 321.5;esophagus: 784.4;skin: 1010.3,prostate: 94.7,Group enriched,12.0,HaCaT: 732.6;hTCEpi: 454.1
70,KRT73,"K6IRS3, KRT6IRS3",ENSG00000186049,Keratin 73,12,52607570-52618559,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044031,Enhanced,,,,,Not detected,Group enriched,7,lymph node: 2.5;skin: 12.1,appendix: 1.0,Not detected,,
71,LGI3,,ENSG00000168481,Leucine rich repeat LGI family member 3,8,22146825-22157084,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024826,,,Approved,Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 76.0;lung: 23.9;skin: 17.3;thyroid gland: 21.6,esophagus: 5.2,Cell line enhanced,,A549: 1.0;SCLC-21H: 1.9;SK-MEL-30: 1.3;WM-115: 1.0
72,PLB1,"FLJ30866, PLB",ENSG00000163803,Phospholipase B1,2,28457145-28643788,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014045,,,Approved,Cytosol,,Mixed,Group enriched,7,skin: 9.4;small intestine: 45.7,testis: 4.2,Cell line enhanced,,BEWO: 3.5
73,PPL,,ENSG00000118898,Periplakin,16,4882507-4960741,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042550, HPA059859",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Ovarian cancer:2.76e-4 (unfavourable),Expressed in all,Group enriched,7,esophagus: 558.8;skin: 149.5,tonsil: 52.0,Cell line enhanced,,HaCaT: 168.9;SiHa: 108.6
74,PSAPL1,,ENSG00000178597,Prosaposin-like 1 (gene/pseudogene),4,7430294-7434973,Predicted secreted proteins,Evidence at protein level,"HPA038013, HPA038482",Approved,,Enhanced,Cytosol,,Mixed,Group enriched,7,skin: 52.7;stomach: 36.5,breast: 6.4,Cell line enhanced,,CACO-2: 13.5;HaCaT: 3.9;hTCEpi: 3.9;RPMI-8226: 16.8
75,SULT1E1,"EST, STE",ENSG00000109193,Sulfotransferase family 1E member 1,4,69810780-69860152,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028213, HPA028728, CAB047344",Enhanced,,Uncertain,Nuclear membrane<br>Cytosol,Cervical cancer:4.06e-4 (favourable),Mixed,Group enriched,7,duodenum: 27.7;liver: 18.7;skin: 7.6;small intestine: 29.7,adrenal gland: 3.1,Group enriched,17.0,HHSteC: 59.4;HSkMC: 23.3;hTCEpi: 19.7;HUVEC TERT2: 16.9
76,TGM5,TGX,ENSG00000104055,Transglutaminase 5,15,43232595-43266857,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,7,esophagus: 8.4;skin: 22.3,breast: 2.3,Cell line enriched,8.0,HEL: 16.7
77,TMPRSS11F,FLJ16046,ENSG00000198092,"Transmembrane protease, serine 11F",4,68053198-68129880,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA026911,Uncertain,,,,,Group enriched,Group enriched,7,esophagus: 16.7;skin: 11.0;tonsil: 3.7,breast: 1.5,Cell line enhanced,,K-562: 1.4
78,WNT16,,ENSG00000002745,Wnt family member 16,7,121325367-121341104,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA027030,Uncertain,,,,,Mixed,Group enriched,7,"cervix, uterine: 8.6;skin: 24.3",seminal vesicle: 2.5,Cell line enhanced,,CAPAN-2: 2.0;HEK93: 4.9;hTEC/SVTERT24-B: 1.6;U-2197: 2.4
79,ABCA12,"DKFZP434G232, ICR2B, LI2",ENSG00000144452,ATP binding cassette subfamily A member 12,2,214931542-215138428,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA078239,,,Approved,Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Group enriched,6,breast: 7.7;skin: 25.2,tonsil: 2.5,Group enriched,6.0,hTCEpi: 28.4;SK-BR-3: 13.8;T-47d: 9.1
80,AC136616.1,,ENSG00000273554,,Unmapped,1139577-1147868,Predicted membrane proteins,Evidence at transcript level,,,,,,,,Group enriched,6,skin: 1.6;testis: 6.9,adrenal gland: 0.6,Cell line enriched,6.0,AN3-CA: 14.2
81,ACP7,"FLJ16165, PAPL, PAPL1",ENSG00000183760,"Acid phosphatase 7, tartrate resistant (putative)",19,39083913-39111493,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA042005, HPA042613",Uncertain,,,,,Group enriched,Group enriched,6,cerebral cortex: 1.8;skin: 6.9;tonsil: 2.3,"epididymis,prostate: 0.5",Cell line enhanced,,hTEC/SVTERT24-B: 9.3;U-87 MG: 43.5
82,ALDH3B2,ALDH8,ENSG00000132746,Aldehyde dehydrogenase 3 family member B2,11,67662162-67681200,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045132,Enhanced,,,,,Mixed,Group enriched,6,breast: 89.9;esophagus: 103.4;skin: 122.2,tonsil: 19.0,Cell line enhanced,,MCF7: 49.6;SK-BR-3: 48.3;T-47d: 12.2
83,ANKRD35,FLJ25124,ENSG00000198483,Ankyrin repeat domain 35,1,145866560-145885866,Predicted intracellular proteins,Evidence at protein level,HPA035453,Enhanced,,,,"Cervical cancer:2.90e-4 (favourable), Breast cancer:9.35e-4 (favourable)",Mixed,Group enriched,6,"cervix, uterine: 30.8;esophagus: 16.6;skin: 69.8",tonsil: 6.1,Cell line enhanced,,ASC TERT1: 6.6;THP-1: 4.5;TIME: 6.9;U-87 MG: 8.1;U-937: 5.9
84,ARSF,,ENSG00000062096,Arylsulfatase F,X,3041471-3112726,Predicted membrane proteins,Evidence at protein level,HPA000549,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,6,adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7,liver: 0.6,Not detected,,
85,CD1A,CD1,ENSG00000158477,CD1a molecule,1,158254137-158258269,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB000009, HPA010734",Enhanced,,,,Cervical cancer:6.37e-4 (favourable),Mixed,Group enriched,6,esophagus: 9.5;skin: 27.0,"lymph node,tonsil: 2.9",Cell line enriched,122.0,MOLT-4: 48.8
86,CDH22,"C20orf25, dJ998H6.1",ENSG00000149654,Cadherin 22,20,46173733-46308498,Predicted membrane proteins,Evidence at transcript level,HPA012164,Uncertain,,,,,Mixed,Group enriched,6,adrenal gland: 2.0;cerebral cortex: 10.2;fallopian tube: 2.3;skin: 5.1,"prostate,seminal vesicle,testis: 0.7",Cell line enriched,23.0,SCLC-21H: 3.7
87,COL6A5,"COL29A1, FLJ35880, VWA4",ENSG00000172752,Collagen type VI alpha 5 chain,3,130345516-130484844,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA043138,Uncertain,,,,,Not detected,Group enriched,6,lung: 3.8;skin: 7.4,"duodenum,stomach: 0.9",Cell line enriched,73.0,HDLM-2: 14.7
88,ENDOU,"P11, PP11, PRSS26",ENSG00000111405,"Endonuclease, poly(U) specific",12,47709734-47725567,Predicted secreted proteins,Evidence at protein level,"HPA012388, HPA067448",Enhanced,,,,Head and neck cancer:6.29e-4 (favourable),Tissue enhanced,Group enriched,6,esophagus: 70.3;skin: 24.9,tonsil: 7.7,Cell line enhanced,,Daudi: 1.6;SK-BR-3: 3.6
89,GJB5,CX31.1,ENSG00000189280,Gap junction protein beta 5,1,34755047-34758512,"Cancer-related genes, Predicted membrane proteins",Evidence at transcript level,HPA038146,Uncertain,,,,Pancreatic cancer:1.54e-4 (unfavourable),Group enriched,Group enriched,6,esophagus: 56.4;skin: 77.4,tonsil: 11.4,Cell line enhanced,,A-431: 25.3;HaCaT: 80.2;HBEC3-KT: 29.1;hTCEpi: 106.2;RT4: 40.6
90,JUP,"CTNNG, DP3, DPIII, PDGB, PKGB",ENSG00000173801,Junction plakoglobin,17,41754604-41786931,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002139, HPA032047",Supported,,Enhanced,Vesicles<br>Plasma membrane<br>Cell Junctions,Renal cancer:2.06e-10 (favourable),Expressed in all,Group enriched,6,esophagus: 491.8;skin: 785.5,fallopian tube: 113.8,Cell line enhanced,,HaCaT: 960.4;RT4: 536.8
91,KLK8,"HNP, neuropsin, ovasin, PRSS19, TADG14",ENSG00000129455,Kallikrein related peptidase 8,19,50996007-51002711,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB019393, HPA035761",Enhanced,,Approved,Vesicles,"Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)",Tissue enhanced,Group enriched,6,esophagus: 77.9;fallopian tube: 20.9;skin: 96.8,breast: 11.0,Group enriched,7.0,A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3
92,KRT3,"CK3, K3",ENSG00000186442,Keratin 3,12,52789685-52796117,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,6,esophagus: 1.3;skin: 1.8,tonsil: 0.2,Group enriched,8.0,HaCaT: 8.3;HMC-1: 4.9
93,KRT31,"Ha-1, KRTHA1",ENSG00000094796,Keratin 31,17,41393724-41397592,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049550, HPA055194",Supported,,,,,Group enriched,Group enriched,6,esophagus: 4.6;skin: 14.4,skeletal muscle: 1.5,Not detected,,
94,LGALS7,"GAL7, LGALS7A, PIG1, TP53I1",ENSG00000205076,Galectin 7,19,38770971-38773492,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001549, CAB032606",Enhanced,,,,,Group enriched,Group enriched,6,breast: 18.1;esophagus: 24.3;skin: 27.7,skeletal muscle: 3.6,Cell line enhanced,,HaCaT: 6.2;SCLC-21H: 1.2
95,LYPD3,C4.4A,ENSG00000124466,LY6/PLAUR domain containing 3,19,43460787-43465660,Predicted membrane proteins,Evidence at protein level,"HPA041529, HPA041797, HPA077859",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,Lung cancer:7.86e-5 (unfavourable),Tissue enhanced,Group enriched,6,esophagus: 673.8;skin: 593.4,tonsil: 114.6,Cell line enhanced,,HaCaT: 85.1;MCF7: 84.1;RT4: 83.0;SK-BR-3: 114.6
96,NMU,,ENSG00000109255,Neuromedin U,4,55595229-55636698,Predicted secreted proteins,Evidence at protein level,HPA025926,Uncertain,,,,"Renal cancer:4.07e-10 (unfavourable), Endometrial cancer:2.60e-5 (unfavourable)",Mixed,Group enriched,6,esophagus: 34.9;skin: 45.4,tonsil: 6.8,Cell line enhanced,,HaCaT: 336.7;K-562: 278.2
97,PERP,"dJ496H19.1, KCP1, KRTCAP1, PIGPC1, THW",ENSG00000112378,"PERP, TP53 apoptosis effector",6,138088505-138107511,Predicted membrane proteins,Evidence at protein level,HPA022269,Enhanced,,,,"Pancreatic cancer:1.05e-5 (unfavourable), Lung cancer:3.73e-4 (unfavourable), Breast cancer:5.46e-4 (unfavourable)",Expressed in all,Group enriched,6,esophagus: 571.9;skin: 1235.5,breast: 151.1,Cell line enhanced,,hTCEpi: 661.0
98,PGLYRP4,"PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67",ENSG00000163218,Peptidoglycan recognition protein 4,1,153330120-153348840,Predicted secreted proteins,Evidence at protein level,CAB025879,,,Approved,Vesicles<br>Plasma membrane,,Group enriched,Group enriched,6,esophagus: 5.8;skin: 18.2,tonsil: 2.1,Cell line enhanced,,HaCaT: 3.4;HDLM-2: 2.4;Karpas-707: 1.4
99,PPFIA3,"KIAA0654, LPNA3, MGC126567, MGC126569",ENSG00000177380,PTPRF interacting protein alpha 3,19,49119389-49151026,Predicted intracellular proteins,Evidence at protein level,"HPA043567, HPA050340",Enhanced,,Uncertain,Nucleoli fibrillar center<br>Vesicles,"Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable)",Expressed in all,Group enriched,6,cerebral cortex: 21.5;skin: 20.2,parathyroid gland: 3.6,Cell line enhanced,,PC-3: 33.5
100,PPM1J,"DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ",ENSG00000155367,"Protein phosphatase, Mg2+/Mn2+ dependent 1J",1,112709994-112715477,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046045,Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5,heart muscle: 4.7,Cell line enhanced,,T-47d: 18.2
101,RNF222,,ENSG00000189051,Ring finger protein 222,17,8390704-8397826,Predicted membrane proteins,Evidence at transcript level,HPA048916,Uncertain,,,,,Tissue enhanced,Group enriched,6,esophagus: 9.7;skin: 4.1;tonsil: 2.0,bone marrow: 0.9,Cell line enriched,7.0,SK-BR-3: 5.1
102,S100A7,"PSOR1, S100A7c",ENSG00000143556,S100 calcium binding protein A7,1,153457744-153460701,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB001453, HPA006997, CAB033766",Enhanced,,,,,Group enriched,Group enriched,6,skin: 326.2;tonsil: 885.9,esophagus: 95.9,Cell line enhanced,,HaCaT: 5.4;SK-BR-3: 10.6
103,SDR16C5,"EPHD-2, RDH-E2, RDHE2",ENSG00000170786,Short chain dehydrogenase/reductase family 16C member 5,8,56300010-56320776,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025224,Enhanced,,,,Head and neck cancer:7.88e-4 (favourable),Mixed,Group enriched,6,breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3,"cervix, uterine: 5.6",Cell line enhanced,,CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
104,SERPINB2,"HsT1201, PAI2, PLANH2",ENSG00000197632,Serpin family B member 2,18,63871692-63903890,"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015480,Supported,,,,Urothelial cancer:1.55e-5 (unfavourable),Tissue enhanced,Group enriched,6,esophagus: 260.7;placenta: 70.3;skin: 105.8;tonsil: 72.9,bone marrow: 22.2,Group enriched,6.0,HaCaT: 611.4;U-138 MG: 792.9;U-2197: 1151.1
105,SLC46A2,"Ly110, TSCOT",ENSG00000119457,Solute carrier family 46 member 2,9,112878920-112890913,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA020098,Approved,,,,,Tissue enhanced,Group enriched,6,"cervix, uterine: 23.3;endometrium: 5.5;epididymis: 5.7;lung: 15.1;skin: 11.3",seminal vesicle: 2.1,Not detected,,
106,SOX21,SOX25,ENSG00000125285,SRY-box 21,13,94709622-94712399,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA048337, HPA064084",Approved,,Approved,Nucleus,"Glioma:1.34e-4 (favourable), Cervical cancer:7.60e-4 (favourable)",Tissue enhanced,Group enriched,6,cerebral cortex: 17.9;esophagus: 6.9;skin: 19.4;stomach: 33.4,tonsil: 3.1,Cell line enhanced,,AF22: 80.6;HAP1: 12.8;NTERA-2: 22.0;PC-3: 11.6
107,TMEM79,"FLJ16057, FLJ32254, MATT, MGC13102",ENSG00000163472,Transmembrane protein 79,1,156282935-156293185,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA055214,Enhanced,,Approved,Nucleoli fibrillar center,"Renal cancer:4.31e-7 (unfavourable), Liver cancer:2.61e-5 (unfavourable)",Expressed in all,Group enriched,6,esophagus: 61.6;prostate: 45.5;skin: 66.8,tonsil: 10.3,Mixed,,
108,TRIM29,"ATDC, FLJ36085",ENSG00000137699,Tripartite motif containing 29,11,120111275-120185529,Predicted intracellular proteins,Evidence at protein level,HPA020053,Enhanced,,Supported,Nucleoplasm<br>Intermediate filaments,"Endometrial cancer:2.88e-4 (unfavourable), Pancreatic cancer:4.46e-4 (unfavourable), Stomach cancer:4.93e-4 (favourable)",Tissue enhanced,Group enriched,6,esophagus: 400.3;skin: 455.7,tonsil: 68.3,Cell line enhanced,,HaCaT: 211.2;hTCEpi: 225.5;RT4: 101.2;SiHa: 190.1
109,TYRP1,"b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP",ENSG00000107165,Tyrosinase related protein 1,9,12685439-12710290,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA000937, CAB002520",Enhanced,,Supported,Vesicles,,Tissue enriched,Group enriched,6,heart muscle: 40.2;skin: 169.1,kidney: 17.0,Cell line enriched,51.0,SK-MEL-30: 1084.9
110,VSIG8,,ENSG00000243284,V-set and immunoglobulin domain containing 8,1,159854316-159862657,Predicted membrane proteins,Evidence at protein level,HPA023219,Uncertain,,,,,Group enriched,Group enriched,6,skin: 13.6;tonsil: 5.8,kidney: 1.7,Not detected,,
111,WNT3,"INT4, MGC131950, MGC138321, MGC138323",ENSG00000108379,Wnt family member 3,17,46762506-46833154,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,6,duodenum: 2.2;parathyroid gland: 4.3;skin: 9.3,cerebral cortex: 0.9,Cell line enhanced,,AF22: 6.9;U-698: 5.4
112,ZIC4,,ENSG00000174963,Zic family member 4,3,147386046-147406860,"Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at transcript level,HPA030194,Uncertain,,Approved,Nucleus<br>Cytosol,,Mixed,Group enriched,6,cerebral cortex: 4.3;skin: 1.4,skeletal muscle: 0.5,Cell line enhanced,,AF22: 17.0;SH-SY5Y: 5.5
113,ASIP,"AGTIL, ASP",ENSG00000101440,Agouti signaling protein,20,34194569-34269344,Predicted secreted proteins,Evidence at protein level,HPA048636,Uncertain,,Supported,Vesicles,,Mixed,Group enriched,5,epididymis: 18.1;ovary: 7.4;skin: 5.7,breast: 2.0,Cell line enhanced,,CACO-2: 2.6
114,CDHR1,"CORD15, KIAA1775, PCDH21, RP65",ENSG00000148600,Cadherin related family member 1,10,84194635-84219621,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA036819,Supported,,,,,Tissue enhanced,Group enriched,5,rectum: 57.9;skin: 252.1,colon: 29.2,Cell line enhanced,,HAP1: 10.5;HEK93: 4.8;HEL: 5.7;RPTEC TERT1: 12.5
115,CLCA2,CLCRG2,ENSG00000137975,Chloride channel accessory 2,1,86424086-86456558,Predicted membrane proteins,Evidence at protein level,HPA047192,Enhanced,,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,,Group enriched,Group enriched,5,esophagus: 126.4;skin: 102.7,tonsil: 22.5,Cell line enhanced,,BEWO: 36.7;HBEC3-KT: 23.7;hTCEpi: 148.8
116,DCST1,FLJ32785,ENSG00000163357,DC-STAMP domain containing 1,1,155033824-155050930,Predicted membrane proteins,Evidence at protein level,HPA060314,Uncertain,,,,,Not detected,Group enriched,5,skin: 3.7;testis: 6.1,small intestine: 0.9,Cell line enhanced,,HaCaT: 1.8;RPMI-8226: 1.7
117,DLX3,,ENSG00000064195,Distal-less homeobox 3,17,49990005-49995224,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,Endometrial cancer:4.61e-4 (unfavourable),Mixed,Group enriched,5,placenta: 10.7;skin: 21.9,thyroid gland: 3.1,Cell line enhanced,,BEWO: 131.0;SK-BR-3: 33.0
118,GJB6,"CX30, DFNA3, ED2, EDH, HED",ENSG00000121742,Gap junction protein beta 6,13,20221971-20232395,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA014846,,,Supported,Cell Junctions,,Tissue enhanced,Group enriched,5,bone marrow: 48.1;cerebral cortex: 39.4;esophagus: 150.1;skin: 32.1,tonsil: 12.2,Cell line enriched,9.0,RT4: 133.4
119,IL1F10,"FKSG75, IL-1F10, IL-1HY2, IL1-theta, MGC11983, MGC119832, MGC119833",ENSG00000136697,Interleukin 1 family member 10 (theta),2,113067970-113075850,Predicted intracellular proteins,Evidence at protein level,HPA059813,Approved,,,,,Tissue enhanced,Group enriched,5,skin: 4.8;tonsil: 2.5,breast: 0.7,Not detected,,
120,IL22RA1,"CRF2-9, IL22R",ENSG00000142677,Interleukin 22 receptor subunit alpha 1,1,24119771-24143121,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,5,colon: 11.3;duodenum: 20.2;esophagus: 10.1;pancreas: 26.1;rectum: 10.9;skin: 38.7;small intestine: 31.3,gallbladder: 4.0,Cell line enhanced,,CACO-2: 9.3;HaCaT: 4.5;Hep G2: 5.5
121,KLK7,"PRSS6, SCCE",ENSG00000169035,Kallikrein related peptidase 7,19,50976482-50984099,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA018994, CAB026342, HPA062126",Enhanced,,Supported,Nuclear membrane<br>Plasma membrane,"Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 68.7;skin: 219.6,fallopian tube: 27.9,Group enriched,6.0,CAPAN-2: 7.1;HaCaT: 28.1
122,MAB21L3,"C1orf161, FLJ38716",ENSG00000173212,Mab-21 like 3,1,116111755-116135240,Predicted intracellular proteins,Evidence at protein level,"HPA039551, HPA046187",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,5,esophagus: 7.5;skin: 7.2,"colon,kidney,rectum: 1.3",Cell line enhanced,,BEWO: 3.7;EFO-21: 8.0;RT4: 10.4
123,MMP27,,ENSG00000137675,Matrix metallopeptidase 27,11,102691487-102705806,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA069097,Approved,,,,,Not detected,Group enriched,5,breast: 6.0;skin: 2.8,bone marrow: 0.8,Not detected,,
124,MYEOV,OCIM,ENSG00000172927,Myeloma overexpressed,11,69294138-69367726,Predicted membrane proteins,Evidence at transcript level,HPA012949,Uncertain,,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)",Mixed,Group enriched,5,adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8,appendix: 1.0,Cell line enhanced,,A-431: 154.1;A549: 74.9;U-2 OS: 38.7
125,NPAS1,"bHLHe11, MOP5, PASD5",ENSG00000130751,Neuronal PAS domain protein 1,19,47019820-47045775,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA043364, HPA072259",,Approved,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.9;skin: 4.4;spleen: 1.8;stomach: 2.6,lymph node: 0.6,Cell line enhanced,,HEK93: 10.1;NB-4: 11.4
126,OVOL3,HOVO3,ENSG00000105261,Ovo like zinc finger 3,19,36111151-36113711,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Not detected,Group enriched,5,skin: 1.0;testis: 2.8,appendix: 0.3,Cell line enhanced,,U-266/84: 2.1
127,RP11-723O4.6,,ENSG00000187695,Uncharacterized protein FLJ43738 ,3,128909874-128971330,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,5,fallopian tube: 10.7;skin: 6.8;testis: 20.3,lung: 2.4,Cell line enhanced,,HAP1: 4.6;HL-60: 4.8
128,SERPINB5,"maspin, PI5",ENSG00000206075,Serpin family B member 5,18,63476761-63505085,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009570, HPA019025, HPA019132, HPA020136",Enhanced,,Supported,Vesicles,"Pancreatic cancer:5.71e-6 (unfavourable), Lung cancer:1.54e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 220.2;skin: 261.8,breast: 44.2,Cell line enhanced,,HaCaT: 1048.4;HBEC3-KT: 281.3;hTCEpi: 583.7
129,SLC1A6,EAAT4,ENSG00000105143,Solute carrier family 1 member 6,19,14950034-15022990,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA041505, HPA044066",Enhanced,,Uncertain,Intermediate filaments,Urothelial cancer:6.88e-6 (unfavourable),Tissue enriched,Group enriched,5,cerebral cortex: 16.2;skin: 8.9;testis: 36.9,epididymis: 3.7,Group enriched,5.0,HAP1: 7.6;NTERA-2: 6.0;U-698: 19.3
130,SYT8,DKFZp434K0322,ENSG00000149043,Synaptotagmin 8,11,1828307-1837521,Predicted membrane proteins,Evidence at transcript level,HPA052700,Uncertain,,Approved,Nucleoplasm<br>Cell Junctions,,Tissue enhanced,Group enriched,5,gallbladder: 26.5;skin: 80.2;urinary bladder: 24.5,seminal vesicle: 8.6,Group enriched,6.0,CAPAN-2: 56.5;hTCEpi: 72.7;T-47d: 25.8
131,TP73,P73,ENSG00000078900,Tumor protein p73,1,3652520-3736201,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002514, CAB003022, HPA027314, HPA044516",Enhanced,,Supported,Nucleoplasm<br>Golgi apparatus,"Endometrial cancer:1.82e-4 (favourable), Cervical cancer:2.98e-4 (favourable), Head and neck cancer:9.50e-4 (favourable)",Mixed,Group enriched,5,fallopian tube: 10.8;skin: 7.7,prostate: 1.8,Cell line enhanced,,SCLC-21H: 21.2
132,TRIM7,"GNIP, RNF90",ENSG00000146054,Tripartite motif containing 7,5,181193924-181205293,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA039213,Approved,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,,Mixed,Group enriched,5,skeletal muscle: 67.7;skin: 22.1,esophagus: 8.6,Cell line enhanced,,HDLM-2: 34.1;PC-3: 18.2
